terization of the genome and structural proteins of hepatitis C virus resolved from infected human liver. J Gen Virol 2004; 85:1497–1507.
19. **Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM**. Structural biology of hepatitis C virus. Hepatology 2004; 39:5–19.
20. **Nelson DR**. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naive patients. Liver Int 2011; 31(suppl 1):53–57.
21. **Pawlotsky JM**. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53:1742–1751.
22. **Monto A, Schooley RT, Lai JC, et al**. Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. Am J Gastroenterol 2010; 105:989–1004.
23. **McCown MF, Rajyaguru S, Kular S, Cammack N, Najera I**. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009; 53:2129–2132.
24. **Cholongitas E, Papatheodoridis GV**. Review article: novel therapeutic options for chronic hepatitis C. Aliment Pharmacol Ther 2008; 27:866–884.
25. **Naggie S, Patel K, McHutchison J**. Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. J Antimicrob Chemother 2010; 65:2063–2069.
26. **Mir HM, Birerdinc A, Younossi ZM**. Monoclonal and polyclonal antibodies against the HCV envelope proteins. Clin Liver Dis 2009; 13:477–486.
27. **Birerdinc A, Younossi ZM**. Emerging therapies for hepatitis C virus. Expert Opin Emerg Drugs 2010; 15:535–544.
28. **Khattab MA**. Targeting host factors: a novel rationale for the management of hepatitis C virus. World J Gastroenterol 2009; 15:3472–3479.
29. **Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al**. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327:198–201.
31. **Gane EJ, Roberts SK, Stedman CA, et al**. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376:1467–1475.

***ADDRESS**: Nizar N. Zein, MD, Department of Gastroenterology and Hepatology, A31, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail zeinn@ccf.org.*

CORRECTION

In the article "Presumed premature ventricular contractions" by Drs. Moises Auron and Donald Underwood (Cleve Clin J Med 2011; 78:812–813), **FIGURE 1** was incorrectly labelled. The corrected figure and legend appear below. The authors wish to thank Philippe Akhrass, MD, from the State University of New York, Brooklyn, and Shahrokh Rafii, MD, from Brookdale University Hospital and Medical Center, Brooklyn, NY, for pointing out this error.



FIGURE 1. The electrocardiogram shows atrial fibrillation. Following the seventh beat, the cycle length "A" is longer than the subsequent cycle "B," giving a long-short sequence that ends in an aberrantly conducted beat that has terminal broadening and a right-bundle-branch-type pattern (white arrow). This is a typical Ashman sequence. The next beat in sequence is slightly aberrant but is returning to the baseline QRS configuration.